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Abstract 
Liposarcoma represents one of the most frequent (10–20%) malignant mesenchymal 
tumors in the adult, affecting mostly the soft tissue of extremities, the trunk or the 
retroperitoneum. This tumor type occurs exceptionally rarely in the gastrointestinal tract 
with only few cases described in the literature. In this case we present a 73-year-old male 
patient who was admitted due to loss of weight, anorexia and postprandial emesis with 
dysphagy. Gastrographin esophagography failed to make precise diagnostics. CT scan of 
the upper gastrointestinal tract revealed a large esophageal tumor filling out the whole 
length of the esophagus. The tumor was removed by parasternocleidomastoidal 
approach with a stapler. Histopathological examination revealed a well-differentiated 
liposarcoma (grade I). Well-differentiated liposarcomas are characterised by amplified 
material of the 12q13–15 chromosomal region, present in the form of giant or ring 
chromosomes and leading to the overexpression of MDM2 and CDK4 genes. MDM2 and 
CDK4 proteins can be detected immunhistochemically, which was the case in the 
reported tumor. Overexpression of these proteins leads to suppression of tumor 
suppressor genes, leading to increased cell survival. 
Introduction 
Liposarcoma represents one of the most frequent (10–20%) malignant mesenchymal 
tumors in the adult. Cytogenetically, three types of liposarcoma can be distinguished: (I) 
well- and dedifferentiated liposarcoma, both containing amplifications of the 12q13–15 in 
form of giant or ring chromosomes, (II) myxoid and round cell liposarcoma (MRCL) 
showing typically balanced t(12;16) or t(12;22) translocation, and (III) pleomorphic  
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liposarcoma with complex heterogenic karyotype alterations. Well-differentiated 
liposarcoma usually occurs in the retroperitoneum or in the deep soft tissue of the 
extremities (mostly high) or trunk [1–3]. It is extremely rare in the esophagus and causes 
unspecific clinical findings such as epigastric pain, dysphagy and persistent nausea. To 
our knowledge esophageal liposarcoma was first described by Mansour in 1983 [3]. To 
date only 14 esophageal liposarcomas have been described. In this case report we describe 
a 73-year-old male patient with a giant, pedunculated, polypoid esophageal well-
differentiated liposarcoma originating in the cervical esophagus to the gastroesophageal 
junction. This is the first case of esophageal well-differentiated liposarcoma with 
immunohistochemically proven overexpression of MDM2 and CDK4. MDM2 (mutated 
double minute) is a negative regulator of p53 [4]; after binding to p53 it may attach a 
polyubiquitin chain to p53. Once polyubiquitinated, p53 is destined to degradation by the 
proteasomal pathway. An induction of MDM2 in a tumor may shift the balance between 
apoptosis and survival towards survival. 
Case Report 
A 73-year-old male patient was admitted due to weight loss and anorexia. He had chronical 
retrosternal pain and postprandial vomiting since four weeks. Concomitantly this patient suffered 
progredient vascular encephalopathy and macroangiopathy IV caused by an escalated diabetes mellitus 
type II (NIDDM) with a HbAIc of 9.3%. Three years earlier, he had undergone a right hemicolectomy 
due to moderately differentiated adenocarcinoma. Two coincidental inflammatory fibroid polyps were 
found in the terminal ileum. 
Initial endoscopy of the upper gastrointestinal tract showed a mass obstructing the distal cervical 
esophagus to the gastroesophageal junction with no mucosal leasons (fig. 1). Additional 
esophagography with gastrographin confirmed the findings of a long-distance esophageal obstruction of 
unknown origin (fig. 2). A CT scan of the caudal cervical organs to abdominal organs revealed a 
heterogenous esophageal mass not directly separable from the esophageal wall (fig. 3). No further 
neoplasias were found in the abdomen. A resection at the mucosal level was performed without 
complications. Following the resection the patient was on parenteral nutrition for 5 days. Recovery was 
uneventful. 12-week follow-up showed a patient in an improved nutritional state and again fully socially 
integrated. 
Findings 
Macroscopy 
Intraoperatively the tumor could be easily separated from the esophageal lumen with 
no adhesions to the wall. The tumor was proximally attached to the esophageal wall by a 
slender stalk (diameter of 1 cm). Resection at the esophageal level was performed by 
stapler technique. The resected specimen consisted of the tumor and was 20 cm long with 
a diameter of 4.5 to 5.5 cm. The mucosal surface of the mass showed no ulcerations or 
necrosis (fig. 4). 
Histopathological Examination 
Microscopically (fig. 5) the tumor was covered by bland squamous epithelium with no 
dysplasia. The main mass of the polyp consisted of sheaths of adipocytes of variable size 
and often hyperchromic, enlarged and pleomorphic nuclei (inset a, arrow). The 
adipocytes showed nuclear immunohistochemical positivity in a reaction with antibodies  
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against MDM2 protein (Zymed, Basel, dilution 1:50) (inset b, arrow) and CDK4 (not 
shown). No nonlipogenic or high-grade areas were identified. A diagnosis of a well-
differentiated liposarcoma was done. The resection margin of the tumor stalk contained 
tumor tissue. 
Discussion 
Lipogenic tumors of the gastrointestinal tract are extremely rare. They are mainly 
found in the mucosa or submucosa of the terminal ileum and large bowel. To our 
knowledge the first case was described by Mansour et al. in 1983 [3]. Only 14 cases of 
esophageal liposarcomas were reported up to date [1–3, 5–18] but without 
immunohistochemical analysis. Age varies between 43 and 73 years and male:female ratio 
is 1.16:1 [5]. The clinical finding may include dysphagy, odynophagy, retrosternal pain, 
respiratory distress, anemia, tumor regurgitation and sudden death by asphyxia. 
Misleading findings in gastroscopy, esophageal manometry and esophagography may be 
found. There are no pathognomonic symptoms or signs, and differential diagnosis 
includes fibrovascular polyp, fibrolipoma, achalasia, bezoars and indirect narrowing by 
mediastinal tumors. Only surgical resection and histological examination allows a precise 
diagnosis [11, 17, 18]. Atypical adipocytes and immunohistochemichal expression of 
MDM2 and/or CDK4 should not be found in fibrovascular polyps or fibrolipomas. 
Surgical treatment varies from endoscopic resection, transcervical, simple enucleation 
or transgastric resection. In this case we preferred the transcervical approach to have an 
option for gut interponate. The most reliable prognostic factors of this tumor are 
histologic subtype, malignancy grade, location and surgical radicality. In patients with 
other types of liposarcomas survival varies between 7 and 104 months [3, 8, 10, 11]. 
The analysis of MDM2 was positive in this case. MDM2 is a negative regulator of p53, 
a tumor suppressor gene which, once activated, leads to cell cycle arrest and apoptosis by 
the mitochondrial pathway. MDM2 has beside a zincfinger domain and p53 binding 
domain a ringfinger domain. A ringfinger has E2 activity and combined with a p53 
binding domain (E3) covalently binds ubiquitin residues to p53. Once ubiquitinated p53 
is destined for degradation by the proteasomal pathway [19]. Therefore, induction of 
MDM2 leads to a suppression of p53 on the proteome level and may shift the cell toward 
survival (fig. 6). The hypothetical tumor suppressive effect of proteasomal inhibition may 
be misleading due to a central role in the regulation of cellular transcriptome. To our 
knowledge a prediction of metastatic behavior after induction of MDM2 cannot be made. 
In this case we found a well-differentiated grade I liposarcoma not radically resected. 
In the case of our 73-year-old patient we did not exceed adiuvant therapies due to a 
palliative situation. Our case is negligible because liposarcomas of the esophagus are 
extremely rare, but the differential diagnosis of a liposarcoma should be considered if 
there is an matching anamnesis. 
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Fig. 1. Esophageal endoscopy. Intraluminal view shows esophageal obturation without (asterisk) 
mucosal ulceration or necrotic areas. 
 
 
Fig. 2. Gastrographin esophagography. Narrowing of the esophageal lumen by a mass of unknown 
origin. Residual lumen is on the ventral side (arrows). 
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Fig. 3. Contrast cervicothoracal CT scan. Frontal reconstructions revealed a long tumor mass filling 
the whole thoracal esophagus, without mediastinal infiltration. 
 
 
Fig. 4. Intraoperative macroscopic view. Large pedunculated tumor mass with 20 cm length and a 
diameter of 4.5–5.5 cm. 
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Fig. 5. Histopathologically normal squamous epithelium covered tumor mass consisting of lipoblasts 
with hyperchromic nuclei (inset a, arrow). Immunohistochemically, nuclear expression of MDM2 was 
demonstrated (inset b, arrow). 
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Fig. 6. Schematic overview of the MDM2 and p53 signalling pathway. The induction of MDM2 leads 
to suppression of p53 by proteasomal degradation. The inhibition of the tumor suppressor gene p53 
leads to suppression of the mitochondrial apoptotic pathway and to survival of the cells. 
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